

Economic plan

This plan identifies the areas prioritised for economic modelling. The final analysis may differ from those described below. The rationale for any differences will be explained in the guideline.

1 Guideline

Asthma: diagnosis, monitoring and chronic asthma management

2 List of modelling questions

Review questions by scope area	Combination of diagnostic tests: In people under investigation for asthma, what is the diagnostic test accuracy and cost effectiveness of combinations of tests?
Population	Adults and children with symptoms suggestive of asthma
Interventions and comparators considered for inclusion	Combinations or sequences of the following diagnostic tests: Spirometry Bronchodilator reversibility test (BDR) Peak expiratory flow test (PEFv) Fractional Exhaled Nitric Oxide (FeNO) Skin prick test IgE Blood eosinophils Mannitol challenge test Methacholine challenge test
Perspective	NHS and personal social services
Outcomes	QALY
Type of analysis	Cost-utility analysis
Modelling software	R studio
Issues to note	

Economic Plan

Review questions by scope area	What is the most clinically and cost-effective sequence in which to introduce additional drugs or combination of drugs for the management of asthma when initial management fails to provide adequate control?
Population	Adults with uncontrolled asthma on initial management with ICS/formoterol combination inhaler
	2 – Adults with uncontrolled asthma on low-dose MART
	3 – Children with uncontrolled asthma on initial management with low-dose ICS + SABA prn
Interventions and comparators considered for inclusion	1 – Low-dose MART vs low/moderate-dose ICS/LABA + SABA prn 2 – Moderate-dose MART vs moderate/high-dose ICS/LABA + SABA prn 3 – Low-dose MART vs low/moderate-dose ICS + SABA prn vs low-dose ICS/LABA + SABA prn
Perspective	NHS and personal social services
Outcomes	QALY
Type of analysis	Cost-utility analysis
Modelling software	Excel
Issues to note	